Waters Launches Peptide Multi-Attribute Method for BioAccord System to Develop and Commercialize Biosimilars

Shots:

• The new peptide MAM workflow for the BioAccord LC-MS system that helps to monitor critical quality attributes of protein-based drugs that can affect the safety & efficacy of innovator drugs and biosimilars
• By integrating BioAccord system on the waters_connect platform, scientists have a sensitive multiplexed method to accurately assess the attributes of protein-based drugs that enable rapid decision-making for product development, manufacturing, and release. The system also monitors product variants, degradation and impurities, and process stability
• The BioAccord system combines the ACQUITY UPLC I-Class and ACQUITY RDa mass detector featuring SmartMS enabled usability features

Click here to­ read full press release/ article | Ref: Businesswire | Image: Twitter